Rivaroxaban

Rivaroxaban is a direct oral anticoagulant (DOAC) and active pharmaceutical ingredient that selectively inhibits Factor Xa. Mediocon Inc supplies high-purity Rivaroxaban API conforming to IP / BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.

Rivaroxaban prevents thrombus formation by directly inhibiting coagulation Factor Xa, reducing thrombin generation. It is indicated for stroke prevention in atrial fibrillation, treatment of DVT and PE, and post-surgical thromboprophylaxis.

Key Features

• High-purity pharmaceutical grade API
• IP / BP / EP / USP compliant
• Full CoA and MSDS documentation
• GMP certified manufacturing

Applications

• Atrial fibrillation stroke prevention
• DVT and PE treatment
• Post-surgical thromboprophylaxis
• Direct oral anticoagulant formulations

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings